|
Section Chair |
Section Secretary |
Past Chair |
Board Member |
Board Member |
|
|
Board Member |
Board Member |
Board Member |
JM Representative |
Interview with Montserrat Alvaro Lozano, Barcelona University
Montserrat Alvaro Lozano discusses the status of food allergy and immunotherapy in pediatrics “"There are many food allergic children who have the risk of |
Section reports
Pediatric section report July 2020
Training and certifications in Pediatric Allergology
Please find here more information on:
European accreditation of Pediatric Allergology Training Centres
Certification as European Specialist in Pediatric Allergology
Task Forces
Food immunotherapy practice in Europe (FIND project)
Chair: Pablo Rodriguez del Rio
Secretary: Montserrat Alvaro
Although adolescents and young people are regarded as a healthy age group, death rates due to food allergy reactions and asthma are highest at this age. Furthermore, healthcare resources are not focused on this age group although this is a critical period for the development of allergic diseases. Besides being life threatening, allergic diseases such as allergic rhinitis and atopic dermatitis can impair work and school performances and negatively impact quality of life, self-esteem and identity in young people.
Chair: Graham Roberts
Secretary: Marta Vazquez Ortiz
Food allergy represents a prevalent disease, affecting around 8% of European children and 2-5% of adults. Standard treatment is based upon avoidance and the use of rescue medication in case of accidental exposure to the trigger. For the last decades, but especially in the last 10 years, important advances have been made in order to provide an etiological treatment to treat this disease. All these treatments, so called food immunotherapy, aim first at protecting the patient by increasing his/her reactivity threshold, and in some cases, patients are even allowed to introduce these foods (mostly milk, egg and peanut) freely in their diets. All these advances are being achieved thanks to the effort of both Academia and Industry by conducting large food immunotherapy trials to provide evidence of its efficacy. However, the way efficacy is measured significantly varies from study to study, limiting the chances to make direct comparisons, and thus, potentially selecting the most suitable for each candidate in the future if these become available.
Chair: Pablo Rodriguez del Rio
Secretary: Montserrat Fernandez Rivas
Targeting the skin barrier in atopic dermatitis
There is a strong need to identify new management approaches for the prevention of atopic dermatitis (AD), due to its substantial burden on patients’ quality of life and health-care resources. In addition, AD is associated with higher risk of developing other atopic diseases. Increasing evidence suggests that skin barrier abnormalities play an essential role in initiation of early AD. The difficulties to target the underlying immune dysregulation, put forward the potential for early interventional approaches targeting skin repair. The aim of this task force is to provide evidence on whether the daily use of topical treatments soon after birth (before the onset of AD) and for the first months of life could reduce the occurrence of AD and/or its severity, thus representing a low cost, easy to apply, safe and effective approach for the primary prevention of AD and atopic march, at least in some phenotypes.
Chair: Elena Galli
Secretary: Pasquale Comberiati
Chronic urticaria in children
Chronic Urticaria in Children (CU-Kids) Task Force: we are establishing a research and clinical network for the optimal, evidence-based diagnosis and management of CU in children. This is taskforce is led by the paediatric section and clinicians who see children with CU. We comprise several relevant stakeholders from dermatology, allergy, primary care, research, immunology, epidemiology, pharmacology, biologicals prescribers, the junior section, patient representation and (through clinical networking, specialist nurses and a pharmacist). We have begun to:
identify clinical centres and colleagues who treat children with urticaria, including attendance at CU focus meetings nationally and internationally. Increase the expertise of participants for research and talks on CU in children, especially with regards to difficult to manage CU and the use of biologicals in the younger age groups:
- several members of the taskforce are involved in clinical audit and service improvement work, and new research involving the medical and supportive management of children with CU across Europe
- develop on the online survey of current clinical practice, needs and recommendations to formulate a report
- plan an EAACI position paper on CU in children for the next taskforce application
Chair: Sophia Tsabouri
Secretary: Tabi Leslie
Perceptions, Beliefs, Attitudes, and Decision making in parents of children with allergic diseases (PARANOID)
The aim of the task force is to assess worries and beliefs, anxiety, allergic diseases perception, medical trust/mistrust and compliance among the parents of allergic children residing in different European countries and to study factors impacting above mentioned outcomes with a particular focus on internet social networks.
Chair: Daniel Munblit
Secretary: Mary Jan Marchisotto
Public Outreach: scoping the needs and developing video resources for the public
The objectives of this task force is to improve awareness of what patients and the public want to know, to obtain qualitative and quantitative assessment of the value of interactive models during the clinical village, and to develop educational material for the online media library and patient portal.
Chair: Helen Brough
Secretary: Eva Untersmayr